Citation Tools
PDFReview
British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin
Other content recommended for you
- A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox®in the treatment of cervical dystonia
- Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases
- Symptomatic and functional outcome of surgical treatment of cervical dystonia
- Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia
- Selective peripheral denervation for cervical dystonia: long-term follow-up
- Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study
- Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study
- Interhemispheric difference of pallidal local field potential activity in cervical dystonia
- Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia
- What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®